Collect plasma samples from patients diagnosed with benign gastric diseases and gastric cancer through endoscopic examination and histopathological examination, and evaluate the diagnostic value of mSEPT9 and mRNF180 alone or in combination for gastric cancer. diagnostic value, gastric cancer, methylation, SEPT9, RNF180
Conditions
Interventions
Gastric cancer patients diagnosed through endoscopic examination and histopathological examination.,Patients with gastric benign diseases confirmed by endoscopic examination and histopathology.
Diagnostic,Diagnostic
Gastric cancer,Benign gastric disease
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) All patients underwent endoscopic examination and histopathological examination, with complete clinical information; 2) Not receiving radiotherapy, chemotherapy, or gastric cancer related surgery; 3) no pregnancy.
Exclusion criteria
Exclusion criteria: 1) Patients who have not undergone endoscopic examination and histopathological examination have incomplete clinical information; 2) Hemolytic samples; 3) Including incomplete history of gastric cancer surgery, other cancer history, or any history of chemotherapy or radiation therapy; 4) Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Combined diagnostic accuracy of methylated SEPT9 and RNF180 At the time that patients test with PCR Sensitivity, Specificity, PPV, NPV, AUROC | — |
Secondary
| Measure | Time frame |
|---|---|
| Independent diagnostic accuracy of methylated SEPT9 or RNF180 At the time that patients test with PCR Sensitivity, Specificity, PPV, NPV, AURO | — |
Countries
China
Contacts
Public ContactJinmei Yang
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed